<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945566</url>
  </required_header>
  <id_info>
    <org_study_id>RG_15-011</org_study_id>
    <secondary_id>2016-000862-49</secondary_id>
    <nct_id>NCT02945566</nct_id>
  </id_info>
  <brief_title>Can the Rectum be Saved by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?</brief_title>
  <acronym>STAR-TREC</acronym>
  <official_title>STAR-TREC:Can the Rectum be Saved by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer is the third most common tumour in the UK, Netherlands and Denmark with&#xD;
      41000, 14000 and 4000 new cases per year respectively. Standard primary radical Total&#xD;
      Mesorectal Excision (TME) surgery is an oncologically effective treatment for early stage&#xD;
      rectal cancer. However, resection of a low rectal tumour requires a permanent stoma in&#xD;
      approximately 5-10% of cases while many more patients have a temporary stoma, some of which&#xD;
      are not reversed. Radical surgery, which evolved to treat locally advanced, symptomatic&#xD;
      tumours, may not be the optimal method of treatment for early screen-detected tumours and an&#xD;
      organ preserving strategy may generate significantly less morbidity without substantially&#xD;
      compromising oncological outcomes.&#xD;
&#xD;
      TREC was a randomised phase II trial to test the feasibility of randomisation between TME and&#xD;
      an organ preserving policy of short course pre-operative radiotherapy (SCPRT) delay followed&#xD;
      by transanal endoscopic microsurgery (TEM). STAR-TREC is a phase II feasibility study that&#xD;
      will evaluate whether it is possible to accelerate the patient recruitment attained in the&#xD;
      TREC study, to 4 per month in the first year of recruitment and 6 per month in the second.&#xD;
      This would demonstrate deliverability of a phase III study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STAR-TREC is a randomised, three arm (1:1:1) study using the following arms:&#xD;
&#xD;
        1. Standard TME surgery (control)&#xD;
&#xD;
        2. Organ saving using:&#xD;
&#xD;
             1. long course concurrent chemoradiation&#xD;
&#xD;
             2. short course radiotherapy For organ-preserving strategies clinical response to&#xD;
                radiotherapy determines the next treatment step. Radiotherapy response is evaluated&#xD;
                using endoscopy and the tumour regression grade, as assessed by MRI. The first&#xD;
                assessment at 11-13 weeks (from radiotherapy start) using MRI and endoscopy will&#xD;
                identify a minority of non-responders who should convert to TME surgery. Patients&#xD;
                demonstrating a satisfactory radiotherapy response at 11-13 weeks will be&#xD;
                reassessed by endoscopy at 16-20 weeks. Re-evaluation determines if the STAR-TREC&#xD;
                criteria for complete clinical response (cCR) are met. Patients who achieve cCR may&#xD;
                progress directly to active surveillance. Those who do not fulfil the criteria for&#xD;
                cCR will progress to excision biopsy with transanal endoscopic microsurgery (TEM).&#xD;
&#xD;
      Patients in the organ saving arm will be assigned to either;&#xD;
&#xD;
      A. Long course concurrent chemoradiation:&#xD;
&#xD;
      Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy,&#xD;
      applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a&#xD;
      week.&#xD;
&#xD;
      or B. Short course preoperative radiotherapy A dose of 25Gy, applied, to the primary tumour&#xD;
      and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.&#xD;
&#xD;
      As a feasibility study, this trial will have recruitment rate as it's primary outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Year 1: randomise at least 4 cases per month internationally</measure>
    <time_frame>1 years</time_frame>
    <description>randomise at least 4 cases per month internationally (n=48)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Year 2: randomise at least 6 cases per month internationally</measure>
    <time_frame>2 years</time_frame>
    <description>randomise at least 6 cases per month internationally (n=72)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achieve funding from international partners</measure>
    <time_frame>1 year</time_frame>
    <description>assessed through seeing whether the study being carried out internationally</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieve recruitment from international partners</measure>
    <time_frame>1 year</time_frame>
    <description>assessed through seeing whether the study being carried out internationally</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ saving rate in the experimental arms at 12 months (from randomisation)</measure>
    <time_frame>1 year</time_frame>
    <description>Percent of relevant organs saved during 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of eligible patients undergoing accurately staged TME surgery</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of eligible patients undergoing accurately staged TME surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients identified by MRI suitable for active monitoring based on mrTRG assessment</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients identified by MRI suitable for active monitoring based on mrTRG assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 year pelvic failure rate</measure>
    <time_frame>3 years</time_frame>
    <description>defined as the proportion of patients in each arm with:&#xD;
unresectable pelvic tumor&#xD;
pelvic tumour requiring beyond TME surgery&#xD;
≤1mm circumferential resection margin after TME surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Absence of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stoma free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time for randomisation without the need for a stoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life by EORTC CR29</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by EORTC CR29 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life by EORTC CR30</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by EORTC CR30 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life by EQ-5D score</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed by EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual dysfunction</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by LARS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel function</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by LARS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder function</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by LARS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual dysfunction in male patients</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by ICICQ-MLUTS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel function in male patients</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by ICICQ-MLUTS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder function in male patients</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by ICICQ-MLUTS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual dysfunction in female patients</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by ICICQ-FLUTS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel function in female patients</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by ICICQ-FLUTS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder function in female patients</measure>
    <time_frame>2 years</time_frame>
    <description>Measured by ICICQ-FLUTS</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Adenocarcinoma of the Rectum</condition>
  <arm_group>
    <arm_group_label>Standard TME surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radical total mesorectal excision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long course concurrent chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short course radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard TME surgery</intervention_name>
    <description>Total mesorectal excision</description>
    <arm_group_label>Standard TME surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long course concurrent chemoradiation</intervention_name>
    <description>Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.</description>
    <arm_group_label>Long course concurrent chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short course radiotherapy</intervention_name>
    <description>A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.</description>
    <arm_group_label>Short course radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven adenocarcinoma of the rectum&#xD;
&#xD;
          -  mriT1-3bN0 (with ≤5mm of mesorectal invasion) rectal tumour or endorectal ultrasound&#xD;
             defined rectal cancer uT1-uT3b (optional: in centres where high quality ERUS is&#xD;
             available and patient unable to tolerate MRI)&#xD;
&#xD;
          -  MDT determines that all of the following treatment options are feasible:&#xD;
&#xD;
               -  TME surgery&#xD;
&#xD;
               -  CRT&#xD;
&#xD;
               -  SCPRT&#xD;
&#xD;
               -  TEM Patients with equivocal radiological lesions e.g. mesorectal,&#xD;
                  retroperitoneal, liver, lung are eligible if agreed by MDT&#xD;
&#xD;
          -  Aged 16 or over in UK (18 or over in the Netherlands and Denmark).&#xD;
&#xD;
          -  Pre-(chemo)radiotherapy treatment, the following criteria must be met :&#xD;
&#xD;
               -  Estimated creatinine clearance &gt;50 mls/min -Absolute neutrophil count &gt;1.5x109/l;&#xD;
                  platelets &gt;100 x 109/L-&#xD;
&#xD;
               -  Serum transaminase &lt;3 x Upper Limit Normal/l (ULN)&#xD;
&#xD;
               -  Bilirubin &lt;1.5 x ULN&#xD;
&#xD;
               -  ECOG performance status 0-1&#xD;
&#xD;
          -  If female and of childbearing potential, must:&#xD;
&#xD;
               -  Have a negative pregnancy test ≤72hours prior to initiating study treatment&#xD;
&#xD;
               -  Agree to avoid pregnancy during and for 6 months after study treatment&#xD;
&#xD;
          -  If male with a partner of childbearing potential, must:&#xD;
&#xD;
               -  Agree to use adequate, medically approved, contraceptive precautions during and&#xD;
                  for 90 days after the last dose of study treatment&#xD;
&#xD;
               -  Patient able and willing to provide written informed consent for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unequivocal evidence of metastatic disease (includes resectable metastases) as&#xD;
             determined by&#xD;
&#xD;
          -  MRI showing:&#xD;
&#xD;
               -  node positive&#xD;
&#xD;
               -  extramural vascular invasion (mriEMVI) positive&#xD;
&#xD;
               -  defined mucinous tumour&#xD;
&#xD;
               -  Maximum tumour diameter &gt; 40mm as measured from everted edges (sagittal)&#xD;
&#xD;
               -  Mesorectal fascia threatened (&lt; 1 mm on MRI)&#xD;
&#xD;
          -  Tumour position anterior, above the peritoneal reflection on MRI or EUS&#xD;
&#xD;
          -  No residual luminal tumour following endoscopic resection&#xD;
&#xD;
          -  Contraindications to radiotherapy including previous pelvic radiotherapy&#xD;
&#xD;
          -  Uncontrolled cardiorespiratory comorbidity (includes patients with inadequately&#xD;
             controlled angina or myocardial infarction within 6 months prior to randomisation)&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase (DPYD) deficiency&#xD;
&#xD;
          -  Known Gilberts disease (hyperbilirubinaemia)&#xD;
&#xD;
          -  Taking warfarin that cannot be discontinued at least 7 days prior to starting&#xD;
             treatment or substituted by low molecular weight heparin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Bach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manjinder Kaur</last_name>
    <phone>0121 415 9104</phone>
    <email>m.kaur@bham.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura MaGill, PhD</last_name>
    <phone>01214159105</phone>
    <email>e.l.magill@bham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Baatrup, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University medical center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans de Wilt, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Bach, MD</last_name>
      <phone>01213718170</phone>
      <email>s.p.bach@bham.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>May 29, 2018</last_update_submitted>
  <last_update_submitted_qc>May 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

